Seifert Lab
@seifertlab.bsky.social
Focus on immune regulators of #PancreaticCancer and #GastricCancer - #SurgeonScientists #TumorImmunology #TranslationalResearch
Excited to share our new publication in OncoImmunology! 🎉 We explore the association of intratumoral regulatory T cells with treatment response to neoadjuvant chemotherapy and prognosis in #GastroesophagealAdenocarcinoma. Read the full paper here: doi.org/10.1080/2162...
Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma
Gastroesophageal junction (GEJ) adenocarcinoma is an increasingly common cancer with complex biology and poor prognosis. The treatment strategy for locally advanced tumors involves multimodal treat...
doi.org
November 6, 2025 at 6:28 AM
Excited to share our new publication in OncoImmunology! 🎉 We explore the association of intratumoral regulatory T cells with treatment response to neoadjuvant chemotherapy and prognosis in #GastroesophagealAdenocarcinoma. Read the full paper here: doi.org/10.1080/2162...
The Department of Visceral, Thoracic, and Vascular Surgery at the Carl Gustav Carus University Hospital is hosting a #WorldPancreaticCancerDay Symposium:
📅 Thursday 20 Nov | 5:00 - 8:00pm
📍 Albertinum
ℹ️ Open to everyone with an interest in pancreatic cancer: weltpankreaskrebstag.de/veranstaltun...
📅 Thursday 20 Nov | 5:00 - 8:00pm
📍 Albertinum
ℹ️ Open to everyone with an interest in pancreatic cancer: weltpankreaskrebstag.de/veranstaltun...
November 2, 2025 at 3:01 PM
The Department of Visceral, Thoracic, and Vascular Surgery at the Carl Gustav Carus University Hospital is hosting a #WorldPancreaticCancerDay Symposium:
📅 Thursday 20 Nov | 5:00 - 8:00pm
📍 Albertinum
ℹ️ Open to everyone with an interest in pancreatic cancer: weltpankreaskrebstag.de/veranstaltun...
📅 Thursday 20 Nov | 5:00 - 8:00pm
📍 Albertinum
ℹ️ Open to everyone with an interest in pancreatic cancer: weltpankreaskrebstag.de/veranstaltun...
Excited to announce a new publication from the @seifertlab.bsky.social identifying soluble TIM-3 and Galectin-9 as novel biomarkers in #GastricCancer and #GastroesophagealAdenocarcinoma. Out today in @cp-iscience.bsky.social: www.cell.com/iscience/ful...
Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer
Current biomarkers for diagnosis and prognosis prediction in gastric (GC) and gastroesophageal
junction (GEJ) cancer have limited accuracy, and the role of soluble immune checkpoints
is unknown. In th...
www.cell.com
October 28, 2025 at 10:27 AM
Excited to announce a new publication from the @seifertlab.bsky.social identifying soluble TIM-3 and Galectin-9 as novel biomarkers in #GastricCancer and #GastroesophagealAdenocarcinoma. Out today in @cp-iscience.bsky.social: www.cell.com/iscience/ful...
Congratulations to Dr. David Digomann, research fellow in the @seifertlab.bsky.social , on receiving the AIO scholarship for #ESMO25. David will also present his latest work, showcasing a novel biomarker for #GastricCancer in a poster presentation - soon to be published.
October 14, 2025 at 5:43 AM
Congratulations to Dr. David Digomann, research fellow in the @seifertlab.bsky.social , on receiving the AIO scholarship for #ESMO25. David will also present his latest work, showcasing a novel biomarker for #GastricCancer in a poster presentation - soon to be published.
Reposted by Seifert Lab
Please join us at the Dresden Immunology Seminar Series
September 11, 2025 at 8:08 AM
Please join us at the Dresden Immunology Seminar Series
Celebrating the 10-year anniversary of the Seifert Lab at University Hospital Dresden and NCT Dresden with a fantastic lab retreat. Grateful for this remarkable team!
August 21, 2025 at 9:21 AM
Celebrating the 10-year anniversary of the Seifert Lab at University Hospital Dresden and NCT Dresden with a fantastic lab retreat. Grateful for this remarkable team!
Reposted by Seifert Lab
Join us at #GI26 to learn about the latest diagnostic and therapeutic strategies in GI cancers to transform your patient outcomes in a program planned by and featuring multidisciplinary experts.
Register today: brnw.ch/21wV49s
Register today: brnw.ch/21wV49s
August 20, 2025 at 4:08 PM
Join us at #GI26 to learn about the latest diagnostic and therapeutic strategies in GI cancers to transform your patient outcomes in a program planned by and featuring multidisciplinary experts.
Register today: brnw.ch/21wV49s
Register today: brnw.ch/21wV49s
Reposted by Seifert Lab
#Cancer does not develop overnight. Researchers at the DKFZ have now developed a method that allows for the first time to reconstruct the evolution of cancerous cells from a single tissue sample.
t1p.de/1jfo4
t1p.de/1jfo4
The evolution of cancer cells decoded
Cancer does not develop overnight. It can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Ce...
t1p.de
July 9, 2025 at 11:16 AM
#Cancer does not develop overnight. Researchers at the DKFZ have now developed a method that allows for the first time to reconstruct the evolution of cancerous cells from a single tissue sample.
t1p.de/1jfo4
t1p.de/1jfo4
Reposted by Seifert Lab
Are you looking to start your #lab in a fantastic scientific 🧪environment, with great colleagues, and in a spectacular place to live?
Then check out our open #junior #faculty position at the Department of Oncology, University of Lausanne, Switzerland:
www.unil.ch/dof/en/home/...
⏰ Deadline 27 June
Then check out our open #junior #faculty position at the Department of Oncology, University of Lausanne, Switzerland:
www.unil.ch/dof/en/home/...
⏰ Deadline 27 June
June 23, 2025 at 5:14 PM
Are you looking to start your #lab in a fantastic scientific 🧪environment, with great colleagues, and in a spectacular place to live?
Then check out our open #junior #faculty position at the Department of Oncology, University of Lausanne, Switzerland:
www.unil.ch/dof/en/home/...
⏰ Deadline 27 June
Then check out our open #junior #faculty position at the Department of Oncology, University of Lausanne, Switzerland:
www.unil.ch/dof/en/home/...
⏰ Deadline 27 June
Reposted by Seifert Lab
www.aacr.org/meeting/aacr...
Abstracts and award applications are due July 15. See you in Boston Sep 28 to Oct 1. @theaacr.bsky.social #PancreaticCancer #2025
Abstracts and award applications are due July 15. See you in Boston Sep 28 to Oct 1. @theaacr.bsky.social #PancreaticCancer #2025
AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research - Emerging Science Driving Transformative Solutions
Meeting overview details for AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research - Emerging Science Driving Transformative Solutions
www.aacr.org
June 2, 2025 at 1:24 PM
www.aacr.org/meeting/aacr...
Abstracts and award applications are due July 15. See you in Boston Sep 28 to Oct 1. @theaacr.bsky.social #PancreaticCancer #2025
Abstracts and award applications are due July 15. See you in Boston Sep 28 to Oct 1. @theaacr.bsky.social #PancreaticCancer #2025
Reposted by Seifert Lab
MATTERHORN manuscript published today in the New England Journal of Medicine. #ASCO25 www.nejm.org/doi/full/10....
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | NEJM
Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig...
www.nejm.org
June 1, 2025 at 8:29 PM
MATTERHORN manuscript published today in the New England Journal of Medicine. #ASCO25 www.nejm.org/doi/full/10....
Reposted by Seifert Lab
More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
June 1, 2025 at 8:41 PM
More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
Reposted by Seifert Lab
Submit your abstract to #CICON25 in #Utrecht and present your research as poster or short talk: cancerimmunotherapyconference.org
May 22, 2025 at 11:46 AM
Submit your abstract to #CICON25 in #Utrecht and present your research as poster or short talk: cancerimmunotherapyconference.org
Reposted by Seifert Lab
#MedNews - First-line treatment with #anlotinib plus #penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to #sorafenib.
Full story 👉 buff.ly/aA3W8IV
#OncSky #HCC
Full story 👉 buff.ly/aA3W8IV
#OncSky #HCC
Novel ICI–TKI combination outplays sorafenib in advanced HCC
First-line treatment with anlotinib plus penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to sorafenib.
buff.ly
May 17, 2025 at 3:15 PM
#MedNews - First-line treatment with #anlotinib plus #penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to #sorafenib.
Full story 👉 buff.ly/aA3W8IV
#OncSky #HCC
Full story 👉 buff.ly/aA3W8IV
#OncSky #HCC
Reposted by Seifert Lab
🚨 FOLFIRINOX vs. GEM Nab Paclitaxel for LAPC @ascocancer.bsky.social
💉 171 pts median PFS 9 months better in FOLFIRINOX group
🎯 FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC
ascopubs.org/doi/10.1200/...
💉 171 pts median PFS 9 months better in FOLFIRINOX group
🎯 FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC
ascopubs.org/doi/10.1200/...
May 19, 2025 at 12:30 PM
🚨 FOLFIRINOX vs. GEM Nab Paclitaxel for LAPC @ascocancer.bsky.social
💉 171 pts median PFS 9 months better in FOLFIRINOX group
🎯 FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC
ascopubs.org/doi/10.1200/...
💉 171 pts median PFS 9 months better in FOLFIRINOX group
🎯 FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC
ascopubs.org/doi/10.1200/...
Reposted by Seifert Lab
Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030.
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
April 24, 2025 at 3:01 PM
Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030.
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
Reposted by Seifert Lab
Do you want to do your #postdoc in #cancerresearch with the most prestigious #fellowship in Europe? Apply to DKFZ Marie Skłodowska Curie MasterClasses by May 19. Projects in #cellandmolecularbiology #genomics #bioinformatics #immunology #medicaltechnology, #epidemiology.
Apply here: t1p.de/nx6tu
Apply here: t1p.de/nx6tu
April 22, 2025 at 1:50 PM
Do you want to do your #postdoc in #cancerresearch with the most prestigious #fellowship in Europe? Apply to DKFZ Marie Skłodowska Curie MasterClasses by May 19. Projects in #cellandmolecularbiology #genomics #bioinformatics #immunology #medicaltechnology, #epidemiology.
Apply here: t1p.de/nx6tu
Apply here: t1p.de/nx6tu
Reposted by Seifert Lab
🚨New publication! 🚨
A new method for evaluating CA19-9 during neoadjuvant therapy, and its role in predicting overall and disease-free survival in BR-PC. A way towards personalised prognostication! 💜💪🏻🙏🏼
doi.org/10.1097/SLA....
A new method for evaluating CA19-9 during neoadjuvant therapy, and its role in predicting overall and disease-free survival in BR-PC. A way towards personalised prognostication! 💜💪🏻🙏🏼
doi.org/10.1097/SLA....
April 16, 2025 at 3:22 PM
🚨New publication! 🚨
A new method for evaluating CA19-9 during neoadjuvant therapy, and its role in predicting overall and disease-free survival in BR-PC. A way towards personalised prognostication! 💜💪🏻🙏🏼
doi.org/10.1097/SLA....
A new method for evaluating CA19-9 during neoadjuvant therapy, and its role in predicting overall and disease-free survival in BR-PC. A way towards personalised prognostication! 💜💪🏻🙏🏼
doi.org/10.1097/SLA....
Reposted by Seifert Lab
Neoadjuvant chemo 🤜🤛 surgery for Resectable PDAC 🇯🇵 RCT
💉 Gemcitabine + S1 median OS 37 months vs. 26
💡 Is neoadjuvant chemo extending survival over upfront surgery?!
🤔 What are your thoughts?! 💭
journals.lww.com/annalsofsurg...
#HPBSky #Surgsky
💉 Gemcitabine + S1 median OS 37 months vs. 26
💡 Is neoadjuvant chemo extending survival over upfront surgery?!
🤔 What are your thoughts?! 💭
journals.lww.com/annalsofsurg...
#HPBSky #Surgsky
April 16, 2025 at 4:54 PM
Neoadjuvant chemo 🤜🤛 surgery for Resectable PDAC 🇯🇵 RCT
💉 Gemcitabine + S1 median OS 37 months vs. 26
💡 Is neoadjuvant chemo extending survival over upfront surgery?!
🤔 What are your thoughts?! 💭
journals.lww.com/annalsofsurg...
#HPBSky #Surgsky
💉 Gemcitabine + S1 median OS 37 months vs. 26
💡 Is neoadjuvant chemo extending survival over upfront surgery?!
🤔 What are your thoughts?! 💭
journals.lww.com/annalsofsurg...
#HPBSky #Surgsky
Reposted by Seifert Lab
📌 Save the date: The next German #Cancer #Congress will take place from February 18 - 21, 2026. The website is now online: www.deutscher-krebskongress.de/english
200 #scholarships are available for students & certain professionals! All information can be found at: t1p.de/hi414
#DKK2026 #MedSky
200 #scholarships are available for students & certain professionals! All information can be found at: t1p.de/hi414
#DKK2026 #MedSky
English
The German Cancer Congress is the oldest, most important and largest scientific congress on oncology in German-speaking countries.
www.deutscher-krebskongress.de
March 28, 2025 at 1:37 PM
📌 Save the date: The next German #Cancer #Congress will take place from February 18 - 21, 2026. The website is now online: www.deutscher-krebskongress.de/english
200 #scholarships are available for students & certain professionals! All information can be found at: t1p.de/hi414
#DKK2026 #MedSky
200 #scholarships are available for students & certain professionals! All information can be found at: t1p.de/hi414
#DKK2026 #MedSky
Reposted by Seifert Lab
Now online in Cancer Discovery: Cytosolic Phospholipase A2 Determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response - by Alexandra Redding, Elda Grabocka, and colleagues doi.org/10.1158/2159...
March 18, 2025 at 2:32 PM
Now online in Cancer Discovery: Cytosolic Phospholipase A2 Determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response - by Alexandra Redding, Elda Grabocka, and colleagues doi.org/10.1158/2159...
Reposted by Seifert Lab
Congrats to Yelena Janjigian and team on their study in @naturemedicine.bsky.social, which presented biomarker analysis of nivolumab plus chemotherapy or ipilimumab in #gastroesophagealcancer. @mskcancercenter.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial - Nature Medicine
Exploratory biomarker analyses of the phase 3 CheckMate 649 trial show that in patients with advanced gastroesophageal cancer, KRAS alterations were associated with greater overall survival (OS) benef...
www.nature.com
March 14, 2025 at 7:58 PM
Congrats to Yelena Janjigian and team on their study in @naturemedicine.bsky.social, which presented biomarker analysis of nivolumab plus chemotherapy or ipilimumab in #gastroesophagealcancer. @mskcancercenter.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Seifert Lab
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis
Chang et al. provide a comprehensive single-cell spatial transcriptomic map of esophageal squamous cell carcinoma, revealing that invasive epithelial cells promote cancer progression by forming a pro-tumor niche with cancer-associated fibroblasts (CAFs).…
dlvr.it
March 14, 2025 at 6:52 PM
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis
👏 Congrats to Sarah Cronjaeger @seifertlab.bsky.social on receiving the Werner-Creutzfeldt-Stipend from #DeutscherPankreasclub. Sarah is investigating a novel therapeutic approach for #PancreaticCancer. Our multicenter NEC4NEOP trial will start to recruit this year.
March 10, 2025 at 8:39 AM
👏 Congrats to Sarah Cronjaeger @seifertlab.bsky.social on receiving the Werner-Creutzfeldt-Stipend from #DeutscherPankreasclub. Sarah is investigating a novel therapeutic approach for #PancreaticCancer. Our multicenter NEC4NEOP trial will start to recruit this year.
Reposted by Seifert Lab
Just announced! Seven new Cancer Grand Challenges – with awards of up to £20m – available for research teams around the world to tackle the biggest questions in cancer research.
Read more: cruk.ink/4ha3LgZ 1/2
Read more: cruk.ink/4ha3LgZ 1/2
March 5, 2025 at 6:07 PM
Just announced! Seven new Cancer Grand Challenges – with awards of up to £20m – available for research teams around the world to tackle the biggest questions in cancer research.
Read more: cruk.ink/4ha3LgZ 1/2
Read more: cruk.ink/4ha3LgZ 1/2